Somryst

Sigurjon Kristjansson, CEO of Nox Health, tells MobiHealthNews why his company made the largest bid for Pear Therapeutics' assets at a recent bankruptcy auction

The company currently has three prescription digital therapeutics available on the market.

 The cognitive behavioral therapy for insomnia program is designed to be an end-to-end virtual experience. 

The new analysis of a Pear Therapeutics-based randomized controlled trial came alongside another investigation that spotted early signs of treatment dropout.

Also: Google promises not to use Fitbit data for targeted advertising; Renalytix AI details its international IPO; New food tracking app relies on machine learning.

Dr. Yuri Maricich, chief medical officer at Pear Therapeutics, speaks on his company's experience bringing a digital therapeutic product through the regulator's experimental program for health software.

Somryst, a prescription digital therapeutic combining cognitive behavioral therapy and personalized sleep restriction, is the first software product to put the FDA's early Precertification Program framework through its paces. 

CEO and President Dr. Corey McCann said that Somryst, a digital treatment for chronic insomnia and depression, is the first software as a medical device product to be submitted through the regulator's pilot pathway.